|
|
News Breaks | | | | February 8, 2013 | | 07:48 EDT |  | LCI | Lannett price target raised to $9 from $6 at Oppenheimer
Oppenheimer increased its price target on Lannett after the company reported higher than expected Q2 EPS. The firm notes that the company may be first-to-file for approval of thalidomide, now believed to represent a generic opportunity of 200M, and it maintains an Outperform rating on the shares. | |
|
News For LCI From The Last 14 Days Check below for free stories on LCI the last two weeks. |
|
|
| There are no results for LCI |
|
|
|
|
|
|
